Tags:CommerceDataDevelopmentDrugIndustryScience
Cydan accelerates compelling science and develops that path for efficiently launching companies to bring those assets to orphan disease patients. Read more.
Total raised: $107M

Investors 3

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
17.10.2017-$34MNew Enterp...vcnewsdail...
14.04.2016Series A$31M-baycitycap...
01.10.2013-$26MBay City C...finsmes.co...
11.04.2013-$16M-finsmes.co...

Mentions in press and media 20

DateTitleDescriptionCategoryAuthorSource
03.01.2019NEA Joins ...CAMBRIDGE, Mass.--(BUSINESS WI...--citybizlis...
09.04.2018NEA-backed...CAMBRIDGE, Mass.--(BUSINESS WI...--citybizlis...
18.10.2017Term Sheet...5 Qs WITH A DEALMAKER Good mo...--fortune.co...
17.10.2017Cydan Rais...CAMBRIDGE, Mass.--(BUSINESS WI...--citybizlis...
17.10.2017Cydan Rais...Cydan, a Cambridge, MA-based d...USA-finsmes.co...
17.10.2017Cydan Secu... CAMBRIDGE, MA, Cydan, an orp...--vcnewsdail...
03.04.2017Cydan Deve...Link to Release Cambridge, ...--baycitycap...
14.04.2016Cydan Deve...CAMBRIDGE, Mass.–(BUSINESS WIR...-Business W...venturebea...
14.04.2016Daily fund...Quartet raised $40M Series B; ...-Mitos Suso...vator.tv/n...
14.04.2016Cydan Rais...Cambridge, MA — Cydan Developm...--baycitycap...
Show more